(PDF) Pharmacoeconomic Analysis of Dasatinib as a

Pharmacoeconomic Analysis of Dasatinib as a Second-Line Therapy in Patients With Chronic Myelogenous Leukemia

Pharmacoeconomics: theory and practice

doi 10.30809/phe.2.2015.2

Full Text

Abstract

Available in full text

Date

June 15, 2015

Authors

Publisher

Moscow Pharmaceutical Society

Related search

Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia

Clinical Lymphoma, Myeloma and Leukemia

Cancer Research

English

Characteristics of Dasatinib- And Imatinib-Resistant Chronic Myelogenous Leukemia Cells

Clinical Cancer Research

Cancer Research

English

Dasatinib Induces Severe Hemorrhagic Colitis in a Patient With Accelerated Phase of Chronic Myelogenous Leukemia

Korean Journal of Internal Medicine

Internal Medicine

English

Budget Impact Analysis or Pharmacological Therapy of Chronic Myeloid Leukemia (Cml) With Nilotinib as the Second-Line Treatment in Russian Federation

Value in Health

Occupational Health

English

Pharmacoeconomic Analysis of Chronic Heart Failure Drug Therapy in Patients With Comorbid Conditions

Rational Pharmacotherapy in Cardiology

Cardiovascular Medicine

English

Imatinib Front-Line Therapy Is Safe and Effective in Patients With Chronic Myelogenous Leukemia With Pre-Existing Liver and/or Renal Dysfunction

Cancer Research

English

Chronic Myelogenous Leukemia

Journal of the National Comprehensive Cancer Network : JNCCN

English

Pcv47 - Pharmacoeconomic Analysis of Chronic Heart Failure Drug Therapy in Patients With Comorbid Conditions

Value in Health

Occupational Health

English

Management of Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: «second-Line» Therapy Possibilities

English